DIAMOND BIOFUND INC (TW:6901) — Market Cap & Net Worth
Market Cap & Net Worth: DIAMOND BIOFUND INC (6901)
DIAMOND BIOFUND INC (TW:6901) has a market capitalization of $366.39 Million (NT$11.63 Billion) as of May 4, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #14108 globally and #554 in its home market, demonstrating a -4.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DIAMOND BIOFUND INC's stock price NT$13.65 by its total outstanding shares 851970000 (851.97 Million). Analyse 6901 cash flow conversion to see how efficiently the company converts income to cash.
DIAMOND BIOFUND INC Market Cap History: 2023 to 2026
DIAMOND BIOFUND INC's market capitalization history from 2023 to 2026. Data shows change from $1.31 Billion to $366.39 Million (-43.44% CAGR).
DIAMOND BIOFUND INC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DIAMOND BIOFUND INC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6901 by Market Capitalization
Companies near DIAMOND BIOFUND INC in the global market cap rankings as of May 4, 2026.
Key companies related to DIAMOND BIOFUND INC by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #140 globally with a market cap of $155.79 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #245 globally with a market cap of $99.82 Billion USD ( CA$137.99 Billion CAD).
- Blackstone Group Inc (NYSE:BX): Ranked #267 globally with a market cap of $94.60 Billion USD.
- KKR & Co LP (NYSE:KKR): Ranked #280 globally with a market cap of $92.43 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #140 | BlackRock Inc | NYSE:BLK | $155.79 Billion | $1061.68 |
| #245 | Brookfield Corporation | TO:BN | $99.82 Billion | CA$61.48 |
| #267 | Blackstone Group Inc | NYSE:BX | $94.60 Billion | $126.35 |
| #280 | KKR & Co LP | NYSE:KKR | $92.43 Billion | $103.68 |
DIAMOND BIOFUND INC Historical Marketcap From 2023 to 2026
Between 2023 and today, DIAMOND BIOFUND INC's market cap moved from $1.31 Billion to $ 366.39 Million, with a yearly change of -43.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$366.39 Million | -17.27% |
| 2025 | NT$442.89 Million | -49.54% |
| 2024 | NT$877.72 Million | -32.99% |
| 2023 | NT$1.31 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of DIAMOND BIOFUND INC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $366.39 Million USD |
| MoneyControl | $366.39 Million USD |
| MarketWatch | $366.39 Million USD |
| marketcap.company | $366.39 Million USD |
| Reuters | $366.39 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.